|Bid||30.02 x 900|
|Ask||30.10 x 1200|
|Day's Range||29.89 - 30.50|
|52 Week Range||14.86 - 34.80|
|Beta (5Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov 10, 2010|
|1y Target Est||35.06|
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), Bausch + Lomb, its leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária).
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today released a report of survey results that offers perspectives from U.S. adults living with irritable bowel syndrome (IBS) during the COVID-19 pandemic. Entitled Patient Perspectives: Living with IBS in a Pandemic, the report provides insights about the symptoms and behaviors of IBS patients over the past year (March 2020 – March 2021). Most notably, more than one-third (37%) of those surveyed acknowledge that the COVID-19 pandemic has made it more challenging to manage their IBS symptoms. The report, which was developed based on a survey conducted by The Fairleigh Dickinson University Poll, also finds concerns about post-pandemic life and insights about the way patients are communicating with their health care providers.
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery